Pharmacoeconomic considerations in the treatment of breast cancer

References

• FerlayJAutierPBoniolMHeanueMColombetMBoylePEstimates of the cancer incidence and mortality in Europe in 2006Ann Oncol200718358159217287242
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardEHaoYXuJThunMJCancer Statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• BerrinoFDeARSantMSurvival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: Results of the EUROCARE-4 studyLancet Oncol20078977378317714991
   PubMed Web of Science ®Google Scholar
• ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin20055527410815761078
   PubMed Web of Science ®Google Scholar
• WoodRBMussHSolinLJOlopadeOIMalignant tumors of the breastDeVitaVTHellmanSRosenbergSAPrinciples and Practice of Oncology7th edPhiladelphia, PALippincott, Williams & Wilkins200514151477
   Google Scholar
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• KeyTJVerkasaloPKBanksEEpidemiology of breast cancerLancet Oncol20012313314011902563
   PubMed Web of Science ®Google Scholar
• AndersonWFChatterjeeNErshlerWBBrawleyOWEstrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results databaseBreast Cancer Res Treat2002761273612408373
   PubMed Web of Science ®Google Scholar
• CampbellJScottRThe costs of treating breast cancer in the US: A synthesis of published evidencePharmacoeconomics200927319920919354340
   PubMed Web of Science ®Google Scholar
• BarronJQuimboRNikamPAmonkarMAssessing the economic burden of breast cancer in a US managed care populationBreast Cancer Res Treat2008109236737717674201
   PubMed Web of Science ®Google Scholar
• MaxWSungHYStarkBThe economic burden of breast cancer in CaliforniaBreast Cancer Res Treat2009116120120718683041
   PubMed Web of Science ®Google Scholar
• LidgrenMWilkingNJonssonBRehnbergCResouce use and costs associated with different states of breast cancerInt J Technol Assess Health Care200723222323117493308
   PubMed Web of Science ®Google Scholar
• LidgrenMWilkingNJonnsonBCost of breast cancer in Sweden in 2002Eur J Health Econ20078151517216424
   PubMed Web of Science ®Google Scholar
• PelletierEMShimBGoodmanSAmonkarMMEpidemiology and economic burden of brain metastases among patients with primary breast cancer: Results from a US claims data analysisBreast Cancer Res Treat2008108229730517577662
   PubMed Web of Science ®Google Scholar
• DeleaTMacKeirnanJBrandmanJRetrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practiceJ Support Oncol20064734134716892696
   PubMedGoogle Scholar
• RaoSKubisiakJGildenDCost of illness associated with metastatic breast cancerBreast Cancer Res Treat2004831253214997052
   PubMed Web of Science ®Google Scholar
• HensleyMLDowellJHerndonJE2ndEconomic outcomes of breast cancer survivorship: CALGB study 79804Breast Cancer Res Treat200591215316115868443
   PubMed Web of Science ®Google Scholar
• LameratoLHavstadSGandhiSJonesDNathansonDEconomic burden associated with breast cancer reoccurrence: Findings from a retrospective analysis on health system dataCancer200610691875188216572409
   PubMed Web of Science ®Google Scholar
• SimmonsRMAdamovichTLSkin-sparing mastectomySurg Clin North Am200383488589912875600
   PubMed Web of Science ®Google Scholar
• FisherBAndersonSRedmondCKWolmarkNWickerhamDLCroninWMReanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancerN Engl J Med199533322145614617477145
   PubMed Web of Science ®Google Scholar
• FisherBAndersonSBryantJTwenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancerN Engl J Med2002347161233124112393820
   PubMed Web of Science ®Google Scholar
• VeronesiUCascinelliNMarianiLTwenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancerN Engl J Med2002347161227123212393819
   PubMed Web of Science ®Google Scholar
• van DongenJAVoogdACFentimanISLong-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trialJ Nat Cancer Inst200092141143115010904087
   PubMedGoogle Scholar
• JacobsonJADanforthDNCowanKHTen-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancerN Engl J Med1995332149079117877647
   PubMed Web of Science ®Google Scholar
• LymanGHGiulianoAESomerfieldMRAmerican Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancerJ Clin Oncol200523307703772016157938
   PubMed Web of Science ®Google Scholar
• GoldhirschAIngleJNGelberRDCoatesASThurlimannBSennHJThresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009Ann Oncol20092081319132919535820
   PubMed Web of Science ®Google Scholar
• SmithIEDowsettMAromatase inhibitors in breast cancerN Engl J Med2003348242431244212802030
   PubMed Web of Science ®Google Scholar
• PartonMSmithIEControversies in the management of patients with breast cancer: Adjuvant endocrine therapy in premenopausal womenJ Clin Oncol200826574575218258982
   PubMed Web of Science ®Google Scholar
• LinNUWinerEPAdvances in adjuvant endocrine therapy for postmenopausal womenJ Clin Oncol200826579880518258989
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trialLancet200235993242131213912090977
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet20053659453606215639680
   PubMed Web of Science ®Google Scholar
• ThurlimannBKeshaviahACoatesASA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med2004350111081109215014181
   PubMed Web of Science ®Google Scholar
• CoombesRCKilburnLSSnowdonCFSurvival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trialLancet2007369956155957017307102
   PubMed Web of Science ®Google Scholar
• JakeszRJonatWGnantMSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trialLancet2005366948445546216084253
   PubMed Web of Science ®Google Scholar
• BoccardoFRubagottiAPuntoniMSwitching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole TrialJ Clin Oncol200523225138514716009955
   PubMed Web of Science ®Google Scholar
• BoccardoFRubagottiAGuglielminiPSwitching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trialAnn Oncol2006Suppl 7vii10vii1416760270
   PubMed Web of Science ®Google Scholar
• JakeszRGreilRGnantMExtended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6aJ Natl Cancer Inst200799241845185318073378
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerN Engl J Med2003349191793180214551341
   PubMed Web of Science ®Google Scholar
• MamounasEPJeongJHWickerhamDLBenefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trialJ Clin Oncol200826121965197118332472
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• BonneterreJThurlimannBRobertsonJFAnastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Clin Oncol200018223748375711078487
   PubMed Web of Science ®Google Scholar
• MouridsenHGershanovichMSunYSuperior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer GroupJ Clin Oncol200119102596260611352951
   PubMed Web of Science ®Google Scholar
• NabholtzJMBuzdarAPollakMAnastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol200018223758376711078488
   PubMed Web of Science ®Google Scholar
• VergoteIBonneterreJThurlimannBRandomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal womenEur J Cancer200036Suppl 4S84S8511056332
   PubMed Web of Science ®Google Scholar
• ParidaensRJDirixLYBeexLVPhase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJ Clin Oncol200826304883489018794551
   PubMed Web of Science ®Google Scholar
• JonatWGnantMBoccardoFEffectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysisLancet Oncol200671299199617138220
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology12009Breast Cancer Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Mar 9, 2010.
   Google Scholar
• SotiriouCPusztaiLGene-expression signatures in breast cancerN Engl J Med2009360879080019228622
   PubMed Web of Science ®Google Scholar
• De LaurentiisMCancelloGD’AgostinoDTaxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trialsJ Clin Oncol2008261445318165639
   PubMed Web of Science ®Google Scholar
• CardosoFBedardPLWinerEPInternational guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapyJ Natl Cancer Inst2009101171174118119657108
   PubMedGoogle Scholar
• CarrickSParkerSWilckenNGhersiDMarzoMSimesJSingle agent versus combination chemotherapy for metastatic breast cancerCochrane Database Syst Rev20052CD00337215846660
   PubMedGoogle Scholar
• SledgeGWNeubergDBernardoPPhase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193)J Clin Oncol200321458859212586793
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJMilesDVukeljaSSuperior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial resultsJ Clin Oncol200220122812282312065558
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• HarrisLFritscheHMennelRAmerican Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerJ Clin Oncol200725335287531217954709
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER-2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• SeidmanADBerryDCirrincioneCRandomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840J Clin Oncol200826101642164918375893
   PubMed Web of Science ®Google Scholar
• RobertNLeyland-JonesBAsmarLRandomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerJ Clin Oncol200624182786279216782917
   PubMed Web of Science ®Google Scholar
• BursteinHJKeshaviahABaronADTrastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane studyCancer2007110596597217614302
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2- overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• BartschRWenzelCAltorjaiGCapecitabine and trastuzumab in heavily pretreated metastatic breast cancerJ Clin Oncol200725253853385817679724
   PubMed Web of Science ®Google Scholar
• vonMGduBASchmidtMMaassNCuferTde JonghFETrastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: German breast group 26/breast international group 03–05 studyJ Clin Oncol200927121999200619289619
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER-2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJBlackwellKLBursteinHA randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER-2+ metastatic breast cancer progressing on trastuzumab therapyJ Clin Oncol20092620 Suppl Abstr 1015.
   Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMTrastuzumab after adjuvant chemotherapy in HER-2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• JoensuuHKellokumpu-LehtinenPLBonoPAdjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerN Engl J Med2006354880982016495393
   PubMed Web of Science ®Google Scholar
• RobertNJEirmannWPienkowskiTBCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-upJ Clin Oncol20072518S Abstr 19647.
   Google Scholar
• HillnerBEIngleJNChlebowskiRTAmerican Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerJ Clin Oncol200321214042405712963702
   PubMed Web of Science ®Google Scholar
• TheriaultRLLiptonAHortobagyiGNPamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study GroupJ Clin Oncol199917384685410071275
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDHDuganWJrZoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesionCancer20041001364314692022
   PubMed Web of Science ®Google Scholar
• DielIJBodyJJLichinitserMRImproved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancerEur J Cancer200440111704171215251160
   PubMed Web of Science ®Google Scholar
• FolkestadLBjarnasonNHBjerregaardJKBrixenKThe effect of aromatase inhibitors on bone metabolismBasic Clin Pharmacol Toxicol2009104131019152547
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA17J Natl Cancer Inst200597171262127116145047
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol20082681231123818250349
   PubMed Web of Science ®Google Scholar
• Tan-ChiuEYothersGRomondEAssessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31J Clin Oncol200523317811781916258083
   PubMed Web of Science ®Google Scholar
• TelliMLHuntSACarlsonRWGuardinoAETrastuzumab-related cardiotoxicity: Calling into question the concept of reversibilityJ Clin Oncol200725233525353317687157
   PubMed Web of Science ®Google Scholar
• LinNUWinerEPBrain metastases: The HER-2 paradigmClin Cancer Res20071361648165517363517
   PubMed Web of Science ®Google Scholar
• EckermannSDMartinAJStocklerMRSimesRJThe benefits and costs of tamoxifen for breast cancer preventionAust N Z J Public Health2003271344014705265
   PubMed Web of Science ®Google Scholar
• KarnonJBrownJon behalf of the ABC Steering CommitteeTamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: A stochastic evaluationPharmacoeconomics200220211913711888364
   PubMed Web of Science ®Google Scholar
• ThompsonDTaylorDCMontoyaELWinerEPJonesSEWeinsteinMCCost effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early stage breast cancerValue in Health200710536737617888101
   PubMed Web of Science ®Google Scholar
• RisebroughNAVermaSTrudeauMMittmannNCost effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for post menopausal women with primary breast cancerCancer2007110349950817592825
   PubMed Web of Science ®Google Scholar
• LundkvistJWilkingNHolmbergSJonnsonLCost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early stage breast cancer after 2–3 years treatment with tamoxifen in SwedenBreast Cancer Res Treat2007102328929917033927
   PubMed Web of Science ®Google Scholar
• HillnerBERadiceDCost effectiveness of exemestane compared with megestrol in patients with advanced breast carcinomaCancer200191348448911169930
   PubMed Web of Science ®Google Scholar
• LindgrenPJonssonBRadaelliARadiceDCost effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: A model for Europe and AustraliaPharmacoeconomics200220210110811888362
   PubMed Web of Science ®Google Scholar
• NuijtenMMeesterLWaibelFWaitSCost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UKPharmacoeconomics199916437939710623366
   PubMed Web of Science ®Google Scholar
• WardSSimpsonEDavisSHindDReesAWilkinsonATaxanes for the adjuvant treatment of early breast cancer: Systematic review and economic evaluationHealth Technol Assess200711401144
   Web of Science ®Google Scholar
• LimwattananonSLimwattananonCMaoleekulpairojSSoparatanapaisalNCost effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancerJ Medical Assoc Thai2006895690698
   PubMedGoogle Scholar
• BrownREHuttonJBurrellACost effectiveness of treatment options in advanced breast cancer in the UKPharmacoeconomics200119111091110211735676
   PubMed Web of Science ®Google Scholar
• LeungPPTannockIFOzaAMPuodziunasADranitsarisGCost-utility analysis of chemotherapy using paclitaxel, docetaxel or vinorelbine for patients with anthracycline-resistant breast cancerJ Clin Oncol199917103082309010506603
   PubMed Web of Science ®Google Scholar
• VuTEllardSSpeersCHSurvival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: A population based evaluationAnn Oncol200819346146418006892
   PubMed Web of Science ®Google Scholar
• LiNvan AgthovenMWillemsePHUyl-de GrootCAA cost-utility analysis comparing second line chemotherapy schemes in patients with metastatic breast cancerAnti-Cancer Drugs200112653354011460000
   PubMed Web of Science ®Google Scholar
• VermaSIllersichALPopulation based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancerOncologist20038323224012773745
   PubMed Web of Science ®Google Scholar
• RavasioRGiulianiGVeronesiACost-efficacy of capecitabine and docetaxel in combination compared with docetaxel monotherapy in patients with metastatic breast cancer pre-treated with anthracyclinesPharmacoeconomics2005715966
   Google Scholar
• VermaSMaraninchiDO’ShaughnessyJCapecitabine plus docetaxel combination therapyCancer2005103122455246515892043
   PubMed Web of Science ®Google Scholar
• TakedaALJonesJLovemanETanSCCleggAJThe clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: A systematic review and economic evaluationHealth Technol Assess.20071119iiiixxi162
   Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceAdvanced breast cancer: Diagnosis and treatment NICE technology appraisal guidance. Number 62, 2009. Available from: www.nice.org.uk/pdf/BreastcancerlapatinibFAD.pdf. Accessed March 07, 2010.
   Google Scholar
• ChanALLeungHWLuCLLinSJCost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: A systematic reviewAnn Pharmacother200943229630319193576
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceTrastuzumab for the adjuvant treatment of early stage HER2-positive breast cancer NICE technology appraisal guidance. 2006. Available from: www.nice.org.uk/nicemedia/pdf/TA107guidance.pdf. Accessed March 9, 2010.
   Google Scholar
• VanVICanonJLCocquytVTrastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authoritiesActa Clin Belg200964210011219432022
   PubMed Web of Science ®Google Scholar
• NeytMHuybrechtsMHulstaertFVrijensFRamaekersDTrastuzumab in early stage breast cancer: A cost effectiveness analysis for BelgiumHealth Policy20088714615918164510
   PubMed Web of Science ®Google Scholar
• MillarJAMillwardMJCost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A lifetime modelPharmacoeconomics200725542944217488140
   PubMed Web of Science ®Google Scholar
• BottemanMBarghoutVStephensJHayJBrandmanJAaproMCost effectiveness of bisphsphonates in the management of breast cancer patients with bone metastasesAnn Oncol20061771072108216670202
   PubMed Web of Science ®Google Scholar
• GuestJFCleggJPDavieAMMcCloskeyECosts and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UKCurr Med Res Opin200521580581515969880
   PubMed Web of Science ®Google Scholar
• SlofJBadiaXLizanLZoledronic acid versus pamidronate: Cost-minimization in bone metastasisJ Med Econ20058112
   Google Scholar
• De CockEHuttonJCanneyPBodyJJBarrett-LeeMPLewisGCost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United KingdomClin Ther20052781295131016199254
   PubMed Web of Science ®Google Scholar
• ReedSDRadevaJIGlendenningGAColemanRESchulmanKAEconomic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myelomaAm J Clin Oncol200528181615685028
   PubMed Web of Science ®Google Scholar
• HillnerBEWeeksJCDeschCESmithTJPamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysisJ Clin Oncol2000181727910623695
   PubMed Web of Science ®Google Scholar
• DranitsarisGHsuTCost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancerSupport Care Cancer19997427127910423054
   PubMed Web of Science ®Google Scholar
• BodyJJEffectiveness and cost of bisphosphonate therapy in tumor bone diseaseCancer2003973 Suppl85986512548587
   PubMed Web of Science ®Google Scholar
• Burdette-RadouxSMussHBA question of duration: Do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?Clin Breast Cancer20099Suppl 1S37S4119561005
   PubMed Web of Science ®Google Scholar
• DeleaTEEl-OuagariKKarnonJSofryginOCost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspectiveBreast Cancer Res Treat2008108337538717653859
   PubMed Web of Science ®Google Scholar
• OuagariKEKarnonJDeleaTTalbotWBrandmanJCost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancerBreast Cancer Res Treat20071011374916821085
   PubMed Web of Science ®Google Scholar
• KarnonJJohnstonSRJonesTGlendenningAA trial based cost effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancerAnn Oncol200314111629163314581270
   PubMed Web of Science ®Google Scholar
• RocchiAVermaSAnastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysisSupport Care Cancer200614991792716596419
   PubMed Web of Science ®Google Scholar
• LockerGYManselRCellaDDobrezDSorensenSGandhiSKATAC Trialists GroupCost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: A US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trialBreast Cancer Res Treat2007106222923817245540
   PubMed Web of Science ®Google Scholar
• ManselRLockerGFallowfieldLBenedictAJonesDCost-effectiveness analysis of anastrozole vs. tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trialBr J Cancer200797215216117622238
   PubMed Web of Science ®Google Scholar
• MoeremansKAnnemansLCost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer: Analysis based on the ATAC trialInt J Gynecol Cancer200616Suppl 257657817010076
   PubMedGoogle Scholar
• PiskurPSoncMCuferTBorstnarSMrharAPharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: A Slovenian perspectiveAnti-Cancer Drugs200617671972416917219
   PubMed Web of Science ®Google Scholar
• OuagariKEKarnonJDeleaTTalbotWBrandmanJCost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancerBreast Cancer Res Treat20071011374916821085
   PubMed Web of Science ®Google Scholar
• DeleaTEKarnonJSmithREJohnstonSRBrandmanJSungJCGossPECost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early stage breast cancerAm J Manag Care200612737438616834524
   PubMed Web of Science ®Google Scholar
• HindDWardSDeNESimpsonECarrollCWyldLHormonal therapies for early breast cancer: Systematic review and economic evaluationHealth Technol Assess200771126iiixi1
   Web of Science ®Google Scholar
• CuzickJAmbroisineLDavidsonNUse of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trialsLancet200751936995741711172317512856
   PubMed Web of Science ®Google Scholar
• GibsonLJDawsonCKLawrenceDHBlissJMAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenCochrane Database Syst Rev20071CD00337017253488
   PubMed Web of Science ®Google Scholar
• BuzdarADoumaJDavidsonNPhase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetateJ Clin Oncol200119143357336611454883
   PubMed Web of Science ®Google Scholar
• BuzdarAUJonatWHowellAAnastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study GroupCancer1998836114211529740079
   PubMed Web of Science ®Google Scholar
• DombernowskyPSmithIFalksonGLetrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetateJ Clin Oncol19981624534619469328
   PubMed Web of Science ®Google Scholar
• KaufmannMBajettaEDirixLYFeinLEJonesSEZilemboNExemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study GroupJ Clin Oncol20001871399141110735887
   PubMed Web of Science ®Google Scholar
• KarnonJJonesTA stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: For advanced breast cancer in postmenopausal patientsPharmacoeconomics200321751352512696991
   PubMed Web of Science ®Google Scholar
• Advanced breast cancer: Diagnosis and treatment Full Guideline developed for NICE by the National Collaborating Centre for Cancer22009 Available from: http://www.nice.org.uk/nicemedia/pdf/CG81FullGuideline.pdf. Accessed March 9, 2010.
   Google Scholar
• TorrisiRBagnardiVPruneriGAntitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancerBr J Cancer200797680280817712311
   PubMed Web of Science ®Google Scholar
• ForwardDPCheungKLJacksonLRobertsonJFClinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancerBr J Cancer200490359059414760369
   PubMed Web of Science ®Google Scholar
• LiberatoNLMarchettiMBarosiGCost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol200725662563317308267
   PubMed Web of Science ®Google Scholar
• NorumJOlsenJAWistEALonningPETrastuzumab in adjuvant breast cancer therapy: A model based cost-effectiveness analysisActa Oncol200746215316417453363
   PubMed Web of Science ®Google Scholar